Johnson & Johnson 2019 revenue forecast misses expectations [Reuters]
Johnson & Johnson (JNJ)
Last johnson & johnson earnings: 4/14 06:31 am
Check Earnings Report
US:NYSE Investor Relations:
jnj.com
Company Research
Source: Reuters
Johnson & Johnson 2019 revenue forecast misses expectations | Reuters 2 Min Read (Reuters) - Johnson & Johnson on Tuesday forecast 2019 sales that fell short of analysts’ estimates after reporting better-than- expected fourth-quarter profit and revenue. The company said it expects 2019 sales in the range of $80.4 billion to $81.2 billion, compared with the average analyst estimate of $82.69 billion, according to IBES data from Refinitiv. Overall fourth-quarter sales rose to $20.39 billion from $20.20 billion, also topping the Wall Street estimate of $20.20 billion. Pharmaceuticals sales rose 5.3 percent to $10.19 billion in the fourth quarter, led by Crohn’s disease treatment Stelara. Analysts had expected revenue of $10.08 billion for the unit. The company posted net profit of $3.04 billion, or $1.12 per share, for the fourth quarter, compared with a loss of $10.71 billion, or $3.99 per share, a year earlier, when it recorded a $13.6 billion charge related to changes to the U.S. tax
Show less
Read more
Impact Snapshot
Event Time:
JNJ
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
JNJ alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
JNJ alerts
High impacting Johnson & Johnson news events
Weekly update
A roundup of the hottest topics
JNJ
News
- Johnson & Johnson (JNJ) Declines More Than Market: Some Information for Investors [Yahoo! Finance]Yahoo! Finance
- Johnson & Johnson Announces U.S. FDA Approval of TECVAYLI® plus DARZALEX FASPRO® for Relapsed/Refractory Multiple Myeloma, Offering a Potential New Standard of Care as Early as Second Line [Yahoo! Finance]Yahoo! Finance
- Johnson & Johnson (JNJ) had its price target raised by JPMorgan Chase & Co. from $225.00 to $250.00. They now have a "neutral" rating on the stock.MarketBeat
- Johnson & Johnson Announces U.S. FDA Approval of TECVAYLI® plus DARZALEX FASPRO® for Relapsed/Refractory Multiple Myeloma, Offering a Potential New Standard of Care as Early as Second LinePR Newswire
- The Top High Yield ETFs Every Retiree Should Own [Yahoo! Finance]Yahoo! Finance
JNJ
Earnings
- 1/21/26 - Beat
JNJ
Sec Filings
- 3/3/26 - Form 4
- 2/27/26 - Form 144
- 2/23/26 - Form 4
- JNJ's page on the SEC website